The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems

Kayser, Oliver; Lemke, A.; Hernández-Trejo, Norma

doi:10.2174/1389201053167158

Cited by 291 publications

(154 citation statements)

References 25 publications

(26 reference statements)

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Gold particles have been also used in medicine to improve the therapeutic effects of drugs designed to treat arthritis. Currently, due to its inert chemical and physical properties, gold cores are considered to be biocompatible and non-toxic which has enlarged its use for disease diagnosis and therapy [31,32].…”

Section: Resultsmentioning

confidence: 99%

Gold nanoparticle modifies nitric oxide release and vasodilation in rat aorta

et al. 2014

View full text Add to dashboard Cite

Nitric oxide (NO) plays an important role on several biological functions. Recently, it has been reported the possibility of modifying the NO release profile from the NO donors through its coupling to gold nanoparticles (AuNPs). Thus, AuNPs were synthesized and they were exposed to the NO donor ruthenium complex Cis-[Ru(bpy) 2 (NO)(4PySH)].(PF6) 3 termed (Ru-4PySH)-forming AuNPs-{Ru-4PySH} n cluster. Our results indicate that AuNPs do not modify the maximum effect (ME) and potency (pD 2 ) in the vasodilation induced by Ru-4PySH. Both complexes induce similar vascular relaxation in concentration-dependent way. However, the NO released from the complex AuNPs-{Ru-4PySH} n is lower than Ru-4PySH. Both complexes release only NO 0 specie, but AuNPs-{Ru-4PySH} n releases NO in constant way and exclusively in the extracellular medium. In time-course, Ru-4Py-SH was faster than AuNPs-{Ru-4PySH} n in inducing the maximum vasodilation. Inhibition of soluble guanylyl cyclase (sGC) abolished the vasodilation induced by Ru-4PYSH, but not by AuNPs-{Ru-4PySH} n . Nonselective potassium (K + ) channel blocker TEA had no effect on the vasodilation induced by AuNPs-{Ru-4PySH} n , but it reduced the potency to Ru-4PySH. In conclusion, our results suggest that AuNPs can reduce the permeability of NO donor Ru-4PySH due to AuNPs-{Ru-4PySH} n cluster formation. AuNPs reduce NO release, but they do not impair the vasodilator effect induced by the NO donor. Ru-4PySH induces vasodilation by sGC and K + channels activation, while AuNPs-{Ru-4PySH} n activates mainly sGC. Taken together, these findings represent a new pharmacological strategy to control the NO release which could activate selective biological targets.

show abstract

Section: Resultsmentioning

confidence: 99%

Gold nanoparticle modifies nitric oxide release and vasodilation in rat aorta

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, it resulted in up-regulation of connective tissue growth factor (CTGF) in the retina, increasing the risk of fibrosis and tractional retinal detachment. A novel dual-target intervention that involves intravitreal injection of the VEGF inhibitor suggest the advantages of dual-target over single-target interventions in diabetic retina and reveal a novel therapeutic modality for diabetic retinopathy [53].…”

Section: Vascular Endothelial Growth Factor (Vegf) Inhibitorsmentioning

confidence: 99%

Recent Advancements in Diabetes Pharmacotherapy

Woldu¹,

Lenjisa²,

Satessa³

2014

Biochem Pharmacol

View full text Add to dashboard Cite

Background: Diabetes mellitus has reached epidemic proportions in many countries. Current challenges in diabetes mellitus management include: optimizing the use of currently available therapies to ensure adequate glycemic, blood pressure, and lipid control and to reduce complications. Aim of the review is to provide a brief overview of recent advancement in diabetes mellitus management. Method Different published articles were reviewed systematically. Result Current standard of care for Type 2 Diabetes mellitus consists of screening for elevated HbA1c levels or, in some cases, fasting plasma glucose, with diagnosis followed by management with lifestyle modifications and metformin. While Insulin, along with diet, is crucial to the survival of individuals with Type 1Diabetes Mellitus. Despite the known benefits of lifestyle modification, and insulin therapy many individuals still find it harder to maintain a healthier life because of the higher possibilities of sedentary behavior and overeating in the modern world. The success of antidiabetes medication has also been limited by their mechanisms of action, and undesirable side effects. The past 10 years have seen an explosion in the number of new treatments available for diabetes and there are a number of exciting new drugs in development to achieve these goals including oral insulin, islet and pancreatic cell transplant, gene therapy, the incretins, dipeptidyl peptidase-4 inhibitors, peroxisome proliferator-activated receptor inhibitors, and sodium-glucose cotransporter inhibitors to treat Type 2 diabetes Mellitus. Conclusion Current standard of care for diabetes management is not sufficient to provide long run benefits to diabetes patients. Therefore, future remedies with the modifications in insulin delivery system and pharmacogenetic therapeutic approaches could possibly provide the much nodded effect and changes the outcome of diabetes management with new outlook.

show abstract

“…Nanotechnology is relatively new and promising scope in the medicine for disease diagnosis, drug delivery at specific target site, molecular imaging etc. The cancer drug toxicity leads to major complications, several modes for delivery of nanoparticles to tumors, such as liposome mediated drug delivery, biodegradable and biocompatible polymeric nanoparticle delivery [3,4]. The synthesis of nanomaterials remains a scientific challenge, since metal nanoparticles are used in various catalytic applications.…”

Section: Introductionmentioning

confidence: 99%